secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001193125-23-231646
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea Biotherapeutics effects 1-for-25 reverse stock split and reduces authorized shares to 20M
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-25 ratio effective Sept 8, 2023; no fractional shares issued; cash in lieu.
- Authorized common shares reduced from 500M to 20M.
- Proportional adjustments to Series A preferred conversion, outstanding warrants, and equity awards.
- Corporate presentation: adjusted total capitalization ~47.7M shares as-converted as of June 22, 2023.
- 2022 net loss per share restated to $(24.86) on weighted-average shares of 3.37M post-split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523231646/0001193125-23-231646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523231646/d548916d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-231646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer